New Product Update
Beximco Pharmaceuticals Ltd. (BPL), a leading pharmaceutical in Bangladesh having global footprint across 55 countries with its prescription medicine. Beximco Pharma is focused towards developing new products, improving existing products as well as new drug delivery systems. In 2017 BPL has set-out a good start with 5 new launches across Gastrointestinal, Cardiovascular, Women health, Vitamins and Minerals and Ophthalmic portfolios.
Beximco Pharmaceuticals Ltd. (BPL), a leading pharmaceutical in Bangladesh having global footprint across 54 countries with its prescription medicine. Beximco pharma is a forefront in bringing new technology and generic has launched 20 products in 2016 across Cardiovascular, Endocrine Disorders, Antibiotics, Anti-viral, Respiratory and Ophthalmic portfolios. On 4 August 2016, Beximco Pharmaceuticals reached a new high became the first Bangladeshi Pharmaceutical Company to export Carvedilol to the United States of America.
Beximco Pharma has recently launched the revolutionary hepatitis C drug under the brand name Lesovir C which is a combination of Sofosbuvir and Ledipasvir.
Leading drug manufacturer Beximco Pharma today announces the launch of generic version of the wonder drug Sofosbuvir for treating Hepatitis C under the brand name ' Sofovir C'. Sofosbuvir is a revolutionary drug recently launched by Gilead Sciences Inc, under its brand Sovaldi which is considered to be the most effective medication to treat hepatitis C with a cure rate of 90%. This is available as tablet and devoid of side effects that are seen with existing injectable therapies. The breakthrough drug, however, costs $1,000 (Tk. 78,400) per tablet in the developed market making it one of the most expensive medicines in the world.
Beximco Pharmaceuticals Ltd. (BPL), a leading pharmaceuticals in Bangladesh and forefront in bringing new technology and generic, has launched 15 products in 2015 across Cardiovascular, Endocrine Disorders, Antibiotics, Antiviral, Gastrointestinal, Anti-acne, and Antihistamine portfolios.
Beximco Pharmaceuticals Ltd. (BPL) has rolled out a good number of products in January 2014, thanks to our R&D and Marketing team. This launching will meet the therapeutic gap needs across Endocrine Disorders,Corticosteroids, Antibiotics, Cardiovascular, Gastrointestinal, Anti-asthma, and Local anesthetic portfolios of BPL.
During January to September 2013 Beximco pharma has further extended its product line with 21 new products across therapeutic groups of Cardiovascular, Antibiotics, Antifungal, Vitamins & Mineral supplements, Pain management, Erectile Dysfunction (ED) and Anti-diabetics.
Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced Dinovo®, a combination of Naproxen and Esomeprazole Magnesium, for the first time in Bangladesh. Dinovo® is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis without causing NSAID-associated gastric injury.
Beximco Pharmaceuticals Ltd., the largest manufacturer of pressurized metered-dose inhalers (pMDIs) in Bangladesh, recently launched dry powder inhalers (DPIs) that are most suitable to the hot and humid climate of the country.